Impact of Disease-Specific Fears on Pulmonary Rehabilitation Trajectories in Patients with COPD

Thomas Janssens, Zora Van de Moortel, Wolfgang Geidl, Johannes Carl, Klaus Pfeifer, Nicola Lehbert, Michael Wittmann, Konrad Schultz, Andreas von Leupoldt, Thomas Janssens, Zora Van de Moortel, Wolfgang Geidl, Johannes Carl, Klaus Pfeifer, Nicola Lehbert, Michael Wittmann, Konrad Schultz, Andreas von Leupoldt

Abstract

Disease-specific fears predict health status in chronic obstructive pulmonary disease (COPD), but their role in pulmonary rehabilitation (PR) remains poorly understood and especially longer-term evaluations are lacking. We therefore investigated changes in disease-specific fears over the course of PR and six months after PR, and investigated associations with PR outcomes (COPD assessment test (CAT) and St. Georges respiratory questionnaire (SGRQ)) in a subset of patients with COPD (n = 146) undergoing a 3-week inpatient PR program as part of the STAR study (Clinicaltrials.gov, ID: NCT02966561). Disease-specific fears as measured with the COPD anxiety questionnaire improved after PR. For fear of dyspnea, fear of physical activity and fear of disease progression, improvements remained significant at six-month follow-up. Patients with higher disease-specific fears at baseline showed elevated symptom burden (CAT and SGRQ Symptom scores), which persisted after PR and at follow-up. Elevated disease-specific fears also resulted in reduced improvements in Quality of Life (SGRQ activity and impact scales) after PR and at follow-up. Finally, improvement in disease-specific fears was associated with improvement in symptom burden and quality of life. Adjustment for potential confounding variables (sex, smoking status, age, lung function, and depressive symptoms) resulted in comparable effects. These findings show the role of disease-specific fears in patients with COPD during PR and highlight the need to target disease-specific fears to further improve the effects of PR.

Keywords: COPD; anxiety; disease-specific fears; pulmonary rehabilitation.

Conflict of interest statement

The authors declare no conflict of interest. Funders were not involved in the design of the study and collection, management, analysis, interpretation of data, in writing the manuscript, or the decision to submit the report for publication.

Figures

Figure 1
Figure 1
Individual trajectories of dyspnea-related fears with mean trajectories (±95% CI) superimposed.
Figure 2
Figure 2
Individual trajectories of COPD assessment test (CAT) scores for participants with different levels of disease-specific fears (color indicates level of disease-specific fear). Estimated trajectories for participants with disease-specific fear scores 1SD above mean, mean, and 1SD below mean (95% CI) are superimposed. (Panel a): Fear of Dyspnea (FD), (Panel b): Fear of Physical Activity (FPA), (Panel c): Fear of Progression (FPR), (Panel d): Fear of Social Exclusion (FSE), (Panel e): Sleep-Related Worries (SRW).
Figure 3
Figure 3
Individual trajectories of St. Georges respiratory questionnaire (SGRQ) activity scores for participants with different levels of disease-specific fears (color indicates level of disease-specific fear). Estimated trajectories for participants with disease-specific fear scores 1SD above mean, mean, and 1SD below mean (95% CI) are superimposed. (Panel a): Fear of Dyspnea (FD), (Panel b): Fear of Physical Activity (FPA), (Panel c): Fear of Progression (FPR), (Panel d): Fear of Social Exclusion (FSE), (Panel e): Sleep-Related Worries (SRW).
Figure 4
Figure 4
Associations between individual changes in disease-specific fears and COPD assessment test scores for participants with different levels of disease-specific fears (color indicates mean level of disease-specific fear). Estimated associations for participants with disease-specific fear scores 1SD above mean, mean, and 1SD below mean (95% CI) are superimposed. (Panel a): Fear of Dyspnea (FD), (Panel b): Fear of Physical Activity (FPA), (Panel c): Fear of Progression (FPR), (Panel d): Fear of Social Exclusion (FSE), (Panel e): Sleep-Related Worries (SRW).
Figure 4
Figure 4
Associations between individual changes in disease-specific fears and COPD assessment test scores for participants with different levels of disease-specific fears (color indicates mean level of disease-specific fear). Estimated associations for participants with disease-specific fear scores 1SD above mean, mean, and 1SD below mean (95% CI) are superimposed. (Panel a): Fear of Dyspnea (FD), (Panel b): Fear of Physical Activity (FPA), (Panel c): Fear of Progression (FPR), (Panel d): Fear of Social Exclusion (FSE), (Panel e): Sleep-Related Worries (SRW).

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of COPD. [(accessed on 23 August 2019)]; Available online:
    1. Spruit M.A., Pitta F., McAuley E., ZuWallack R.L., Nici L. Pulmonary Rehabilitation and Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2015;192:924–933. doi: 10.1164/rccm.201505-0929CI.
    1. Coventry P.A., Hind D. Comprehensive pulmonary rehabilitation for anxiety and depression in adults with chronic obstructive pulmonary disease: Systematic review and meta-analysis. J. Psychosom. Res. 2007;63:551–565. doi: 10.1016/j.jpsychores.2007.08.002.
    1. McCarthy B., Casey D., DeVane D., Murphy K., Murphy E., Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015:CD003793. doi: 10.1002/14651858.CD003793.pub3.
    1. Spruit M.A., Singh S.J., Garvey C., ZuWallack R., Nici L., Rochester C., Hill K., Holland A.E., Lareau S.C., Man W.D.-C., et al. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. Am. J. Respir. Crit. Care Med. 2013;188:e13–e64. doi: 10.1164/rccm.201309-1634ST.
    1. Matte D.L., Pizzichini M.M., Hoepers A.T., Diaz A.P., Karloh M., Dias M., Pizzichini E. Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies. Respir. Med. 2016;117:154–161. doi: 10.1016/j.rmed.2016.06.006.
    1. Panagioti M., Scott C., Blakemore A., A Coventry P. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int. J. Chronic Obstr. Pulm. Dis. 2014;9:1289–1306.
    1. Ratcliff C.G., Barrera T.L., Petersen N.J., Sansgiry S., Kauth M.R., Kunik M.E., Stanley M.A., Cully J.A. Recognition of anxiety, depression, and PTSD in patients with COPD and CHF: Who gets missed? Gen. Hosp. Psychiatry. 2017;47:61–67. doi: 10.1016/j.genhosppsych.2017.05.004.
    1. Yohannes A.M., Alexopoulos G.S. Depression and anxiety in patients with COPD. Eur. Respir. Rev. 2014;23:345–349. doi: 10.1183/09059180.00007813.
    1. Willgoss T.G., Yohannes A.M. Anxiety Disorders in Patients With COPD: A Systematic Review. Respir. Care. 2013;58:858–866.
    1. Schuler M., Strohmayer M., Mühlig S., Schwaighofer B., Wittmann M., Faller H., Schultz K. Assessment of depression before and after inpatient rehabilitation in COPD patients: Psychometric properties of the German version of the Patient Health Questionnaire (PHQ-9/PHQ-2) J. Affect. Disord. 2018;232:268–275. doi: 10.1016/j.jad.2018.02.037.
    1. Kim H.F.S., Kunik M.E., Molinari V.A., Hillman S.L., Lalani S., Orengo C.A., Petersen N.J., Nahas Z., Goodnight-White S. Functional Impairment in COPD Patients: The Impact of Anxiety and Depression. J. Psychosom. Res. 2000;41:465–471. doi: 10.1176/appi.psy.41.6.465.
    1. Kunik M.E., Roundy K., Veazey C., Souchek J., Richardson P., Wray N.P., Stanley M.A. Surprisingly High Prevalence of Anxiety and Depression in Chronic Breathing Disorders. Chest. 2005;127:1205. doi: 10.1016/S0012-3692(15)34468-8.
    1. Blakemore A., Dickens C., Guthrie E., Bower P., Kontopantelis E., Afzal C., Coventry P.A. Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: Systematic review and meta-analysis. Int. J. Chronic Obstr. Pulm. Dis. 2014;9:501. doi: 10.2147/COPD.S58136.
    1. Schwab P., Dhamane A.D., Hopson S.D., Moretz C., Annavarapu S., Burslem K., Renda A., Kaila S. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int. J. Chronic Obstr. Pulm. Dis. 2017;12:735. doi: 10.2147/COPD.S112256.
    1. Wacker M.E., Kitzing K., Jörres R.A., Leidl R., Schulz H., Karrasch S., Karch A., Koch A., Vogelmeier C.F., Holle R. The contribution of symptoms and comorbidities to the economic impact of COPD: An analysis of the German COSYCONET cohort. Int. J. Chronic Obstr. Pulm. Dis. 2017;12:3437. doi: 10.2147/COPD.S141852.
    1. Laforest L., Roche N., Devouassoux G., Belhassen M., Chouaid C., Ginoux M., Van Ganse E. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. Respir. Med. 2016;117:33–39. doi: 10.1016/j.rmed.2016.05.019.
    1. Divo M., Cote C., de Torres J.P., Casanova C., Marin J.M., Pinto-Plata V., Zulueta J., Cabrera C., Zagaceta J., Hunninghake G., et al. Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2012;186:155–161. doi: 10.1164/rccm.201201-0034OC.
    1. Lou P., Zhu Y., Chen P., Zhang P., Yu J., Zhang N., Chen N., Zhang L., Wu H., Zhao J. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: A cross-sectional case control study. BMC Pulm. Med. 2012;12:53. doi: 10.1186/1471-2466-12-53.
    1. Von Leupoldt A., Taube K., Lehmann K., Fritzsche A., Magnussen H. The Impact of Anxiety and Depression on Outcomes of Pulmonary Rehabilitation in Patients With COPD. Chest. 2011;140:730–736. doi: 10.1378/chest.10-2917.
    1. Papaioannou V.E., Pneumatikos I., Maglaveras N. Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: Current strengths and limitations. Front. Physiol. 2013;4:4. doi: 10.3389/fphys.2013.00174.
    1. A Coventry P., Gemmell I., Todd C.J. Psychosocial risk factors for hospital readmission in COPD patients on early discharge services: A cohort study. BMC Pulm. Med. 2011;11:49. doi: 10.1186/1471-2466-11-49.
    1. Laurin C., Moullec G., Bacon S.L., Lavoie K.L. Impact of Anxiety and Depression on Chronic Obstructive Pulmonary Disease Exacerbation Risk. Am. J. Respir. Crit. Care Med. 2012;185:918–923. doi: 10.1164/rccm.201105-0939PP.
    1. Pikoula M., Quint J.K., Nissen F., Hemingway H., Smeeth L., Denaxas S. Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records. BMC Med. Inform. Decis. Mak. 2019;19:86. doi: 10.1186/s12911-019-0805-0.
    1. Khdour M.R., Hawwa A.F., Kidney J.C., Smyth B.M., McElnay J.C. Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD) Eur. J. Clin. Pharmacol. 2012;68:1365–1373. doi: 10.1007/s00228-012-1279-5.
    1. Paine N.J., Bacon S.L., Bourbeau J., Tan W.C., Lavoie K.L., Aaron S.D., Chapman K.R., FitzGerald J.M., Hernandez P., Marciniuk D.D., et al. Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. Respir. Med. 2018;146:1–9. doi: 10.1016/j.rmed.2018.11.006.
    1. Von Leupoldt A., Janssens T. Could targeting disease specific fear and anxiety improve COPD outcomes? Expert Rev. Respir. Med. 2016;10:835–837. doi: 10.1080/17476348.2016.1198697.
    1. Wortz K., Cade A., Menard J.R., Lurie S., Lykens K., Bae S., Jackson B., Su F., Singh K., Coultas D. A qualitative study of patients’ goals and expectations for self-management of COPD. Prim. Care Respir. J. 2012;21:384–391. doi: 10.4104/pcrj.2012.00070.
    1. De Peuter S., Janssens T., Van Diest I., Stans L., Troosters T., Decramer M., Van den Bergh O., Vlaeyen J.W.S. Dyspnea-related anxiety: The Dutch version of the Breathlessness Beliefs Questionnaire. Chronic Respir. Dis. 2011;8:11–19. doi: 10.1177/1479972310383592.
    1. Keil D.C., Stenzel N.M., Kühl K., Vaske I., Mewes R., Rief W., Kenn K. The impact of chronic obstructive pulmonary disease-related fears on disease-specific disability. Chronic Respir. Dis. 2014;11:31–40. doi: 10.1177/1479972313516881.
    1. Vlaeyen J.W.S., Crombez G., Linton S.J. The fear-avoidance model of pain. Pain. 2016;157:1588–1589. doi: 10.1097/j.pain.0000000000000574.
    1. Lethem J., Slade P., Troup J., Bentley G. Outline of a fear-avoidance model of exaggerated pain perception—I. Behav. Res. Ther. 1983;21:401–408. doi: 10.1016/0005-7967(83)90009-8.
    1. Kühl K., Kuhn C., Kenn K., Rief W. Der COPD-Angst-Fragebogen (CAF): Ein neues Instrument zur Erfassung krankheitsspezifischer Ängste bei COPD-Patienten. PPmP-Psychother. Psychosom. Med. Psychol. 2011;61:e1–e9.
    1. Vercoulen J.H., Daudey L., Molema J., Vos P.J., Peters J.B., Top M., Folgering H. An integral assessment framework of health status in chronic obstructive pulmonary disease (COPD) Int. J. Behav. Med. 2008;15:263–279. doi: 10.1080/10705500802365474.
    1. Peters J.B., Daudey L., Heijdra Y.F., Molema J., Dekhuijzen P.N.R., Vercoulen J.H. Development of a battery of instruments for detailed measurement of health status in patients with COPD in routine care: The Nijmegen Clinical Screening Instrument. Qual. Life Res. 2009;18:901–912. doi: 10.1007/s11136-009-9502-2.
    1. Janssens T., De Peuter S., Stans L., Verleden G., Troosters T., Decramer M., Van den Bergh O. Dyspnea Perception in COPD Association Between Anxiety, Dyspnea-Related Fear, and Dyspnea in a Pulmonary Rehabilitation Program. Chest. 2011;140:618–625. doi: 10.1378/chest.10-3257.
    1. Reijnders T., Schuler M., Wittmann M., Jelusic D., Troosters T., Janssens W., Stenzel N.M., Schultz K., von Leupoldt A. The Impact of Disease-Specific Fears on Outcome Measures of Pulmonary Rehabilitation in Patients with COPD. Respir. Med. 2018;146:87–95. doi: 10.1016/j.rmed.2018.12.004.
    1. Esser R.W., Stoeckel M.C., Kirsten A., Watz H., Taube K., Lehmann K., Petersen S., Magnussen H., Von Leupoldt A. Structural Brain Changes in Patients With COPD. Chest. 2016;149:426–434. doi: 10.1378/chest.15-0027.
    1. Harris D., Hayter M., Allender S. Improving the uptake of pulmonary rehabilitation in patients with COPD: Qualitative study of experiences and attitudes. Br. J. Gen. Pract. 2008;58:703–710. doi: 10.3399/bjgp08X342363.
    1. Peters J.B., Boer L.M., Molema J., Heijdra Y.F., Prins J.B., Vercoulen J.H. Integral Health Status-Based Cluster Analysis in Moderate–Severe COPD Patients Identifies Three Clinical Phenotypes: Relevant for Treatment as Usual and Pulmonary Rehabilitation. Int. J. Behav. Med. 2017;24:571–583. doi: 10.1007/s12529-016-9622-3.
    1. Stenzel N.M., Vaske I., Kühl K., Kenn K., Rief W. Prediction of end-of-life fears in COPD—Hoping for the best but preparing for the worst. Psychol. Health. 2015;30:1–18. doi: 10.1080/08870446.2015.1014816.
    1. Herigstad M., Faull O.K., Hayen A., Evans E., Hardinge F.M., Wiech K., Pattinson K.T. Treating breathlessness via the brain: Changes in brain activity over a course of pulmonary rehabilitation. Eur. Respir. J. 2017;50:1701029. doi: 10.1183/13993003.01029-2017.
    1. Solomon B.K., Wilson K.G., Henderson P.R., Poulin P.A., Kowal J., McKim D.A. A Breathlessness Catastrophizing Scale for chronic obstructive pulmonary disease. J. Psychosom. Res. 2015;79:62–68. doi: 10.1016/j.jpsychores.2014.11.020.
    1. Zoeckler N., Kenn K., Kuehl K., Stenzel N., Rief W. Illness perceptions predict exercise capacity and psychological well-being after pulmonary rehabilitation in COPD patients. J. Psychosom. Res. 2014;76:146–151. doi: 10.1016/j.jpsychores.2013.11.021.
    1. Fischer M.J., Scharloo M., Abbink J., van ’t Hul A., van Ranst D., Rudolphus A., Weinman J., Rabe K.F., Kaptein A.A. Concerns About Exercise Are Related to Walk Test Results in Pulmonary Rehabilitation for Patients with COPD. Int. J. Behav. Med. 2012;19:39–47. doi: 10.1007/s12529-010-9130-9.
    1. Geidl W., Semrau J., Streber R., Lehbert N., Wingart S., Tallner A., Wittmann M., Wagner R., Schultz K., Pfeifer K. Effects of a brief, pedometer-based behavioral intervention for individuals with COPD during inpatient pulmonary rehabilitation on 6-week and 6-month objectively measured physical activity: Study protocol for a randomized controlled trial. Trials. 2017;18:396. doi: 10.1186/s13063-017-2124-z.
    1. Miller M.R. Standardisation of spirometry. Eur. Respir. J. 2005;26:319–338. doi: 10.1183/09031936.05.00034805.
    1. Quanjer P.H., Stanojevic S., Cole T.J., Baur X., Hall G.L., Culver B.H., Enright P.L., Hankinson J.L., Ip M.S., Zheng J., et al. multi-ethnic reference values for spirometry for the 3–95 year age range: The global lung function 2012 equations. Eur. Respir. J. 2012;40:1324–1343. doi: 10.1183/09031936.00080312.
    1. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS Statement Guidelines for the Six-Minute Walk Test. Am. J. Respir. Crit. Care Med. 2002;166:111–117. doi: 10.1164/ajrccm.166.1.at1102.
    1. Wingart S., Lehbert N., Krämer B., Huber V., Fuchs S., Wittmann M., Jelusic D., Schuler M., Schultz K. Is a double 6-min walk test required as part of the routine assessment of pulmonary rehabilitation in COPD patients? Eur. Respir. J. 2014;44:P1293.
    1. Jenkins S.C. 6-Minute walk test in patients with COPD: Clinical applications in pulmonary rehabilitation. Physiotherapy. 2007;93:175–182.
    1. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.-H., Leidy N.K. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009;34:648–654. doi: 10.1183/09031936.00102509.
    1. Ringbaek T., Martinez G., Lange P. A Comparison of the Assessment of Quality of Life with CAT, CCQ, and SGRQ in COPD Patients Participating in Pulmonary Rehabilitation. COPD J. Chronic Obstr. Pulm. Dis. 2012;9:12–15. doi: 10.3109/15412555.2011.630248.
    1. Gupta N., Pinto L.M., Morogan A., Bourbeau J. The COPD assessment test: A systematic review. Eur. Respir. J. 2014;44:873–884. doi: 10.1183/09031936.00025214.
    1. Alma H., de Jong C., Jelusic D., Wittmann M., Schuler M., Blok B.F., Kocks J., Schultz K., van der Molen T. Health status instruments for patients with COPD in pulmonary rehabilitation: Defining a minimal clinically important difference. NPJ Prim. Care Resp. Med. 2016;26:16041. doi: 10.1038/npjpcrm.2016.41.
    1. Von Leupoldt A., Reijnders T., Schuler M., Wittmann M., Jelusic D., Schultz K. Validity of a Self-administered Questionnaire Version of the Transition Dyspnea Index in Patients with COPD. COPD J. Chronic Obstr. Pulm. Dis. 2017;14:66–71. doi: 10.1080/15412555.2016.1246522.
    1. Witek T., Mahler D. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur. Respir. J. 2003;21:267–272. doi: 10.1183/09031936.03.00068503a.
    1. Mahler D.A., Weinberg D.H., Wells C.K., Feinstein A.R. The Measurement of Dyspnea: Contents, Interobserver Agreement, and Physiologic Correlates of Two New Clinical Indexes. Chest. 1984;85:751–758. doi: 10.1378/chest.85.6.751.
    1. Jones P.W., Quirk F.H., Baveystock C.M. The St George’s Respiratory Questionnaire. Respir. Med. 1991;85:25–31. doi: 10.1016/S0954-6111(06)80166-6.
    1. Gräfe K., Zipfel S., Herzog W., Löwe B. Screening psychischer Störungen mit dem “Gesundheitsfragebogen für Patienten (PHQ-D)”. Diagnostica. 2004;50:171–181. doi: 10.1026/0012-1924.50.4.171.
    1. Bates D., Mächler M., Bolker B., Walker S. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015;67:1–48. doi: 10.18637/jss.v067.i01.
    1. Lenth R., Singmann H., Love J., Buerkner P., Herve M. Emmeans: Estimated Marginal Means, aka Least-Squares Means. [(accessed on 23 August 2019)]; Available online: .
    1. Kuznetsova A., Brockhoff P.B., Christensen R.H.B. lmerTest: Tests in Linear Mixed Effects Models. [(accessed on 21 August 2019)]; Available online: .
    1. Carrieri-Kohlman V., Gormley J.M., Douglas M.K., Paul S.M., Stulbarg M.S. Exercise Training Decreases Dyspnea and the Distress and Anxiety Associated with It. Chest. 1996;110:1526–1535. doi: 10.1378/chest.110.6.1526.
    1. Wadell K., Webb K.A., Preston M.E., Amornputtisathaporn N., Samis L., Patelli J., Guenette J.A., O’Donnell D.E. Impact of Pulmonary Rehabilitation on the Major Dimensions of Dyspnea in COPD. COPD J. Chronic Obstr. Pulm. Dis. 2013;10:425–435. doi: 10.3109/15412555.2012.758696.
    1. McNicholas W.T., Verbraecken J., Marín J.M. Sleep disorders in COPD: The forgotten dimension. Eur. Respir. Rev. 2013;22:365–375. doi: 10.1183/09059180.00003213.
    1. Scharf S.M., Maimon N., Simon-Tuval T., Bernhard-Scharf B.J., Reuveni H., Tarasiuk A. Sleep quality predicts quality of life in chronic obstructive pulmonary disease. Int. J. Chronic Obstruct. Pulm. Dis. 2011;6:1. doi: 10.2147/COPD.S15666.
    1. Zeidler M.R., Martin J.L., Kleerup E.C., Schneider H., Mitchell M.N., Hansel N.N., Sundar K., Schotland H., Basner R.C., Wells J.M., et al. Sleep disruption as a predictor of quality of life among patients in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS) Sleep. 2018;41:zsy044. doi: 10.1093/sleep/zsy044.
    1. Reijnders T., Schuler M., Jelusic D., Troosters T., Janssens W., Schultz K., Leupoldt A. von The Impact of Loneliness on Outcomes of Pulmonary Rehabilitation in Patients with COPD. COPD J. Chronic Obstr. Pulm. Dis. 2018;15:446–453. doi: 10.1080/15412555.2018.1471128.
    1. Halding A.-G., Wahl A., Heggdal K. ‘Belonging’. ‘Patients’ experiences of social relationships during pulmonary rehabilitation. Disabil. Rehabil. 2010;32:1272–1280. doi: 10.3109/09638280903464471.
    1. Spruit M.A., Pitta F., Garvey C., ZuWallack R.L., Roberts C.M., Collins E.G., Goldstein R., McNamara R., Surpas P., Atsuyoshi K., et al. Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur. Respir. J. 2014;43:1326–1337. doi: 10.1183/09031936.00145613.
    1. Desveaux L., Janaudis-Ferreira T., Goldstein R., Brooks D. An International Comparison of Pulmonary Rehabilitation: A Systematic Review. COPD J. Chronic Obstr. Pulm. Dis. 2015;12:144–153. doi: 10.3109/15412555.2014.922066.
    1. Livermore N., Sharpe L., McKenzie D. Prevention of panic attacks and panic disorder in COPD. Eur. Respir. J. 2010;35:557–563. doi: 10.1183/09031936.00060309.
    1. Heslop-Marshall K., Baker C., Carrick-Sen D., Newton J., Echevarria C., Stenton C., Jambon M., Gray J., Pearce K., Burns G., et al. Randomised controlled trial of cognitive behavioural therapy in COPD. ERJ Open Res. 2018;4:00094–2018. doi: 10.1183/23120541.00094-2018.
    1. Barrera T.L., Grubbs K.M., Kunik M.E., Teng E.J. A Review of Cognitive Behavioral Therapy for Panic Disorder in Patients with Chronic Obstructive Pulmonary Disease: The Rationale for Interoceptive Exposure. J. Clin. Psychol. Med. Settings. 2014;21:144–154. doi: 10.1007/s10880-014-9393-4.
    1. Wouters E.F., Wouters B.B., Augustin I.M., Houben-Wilke S., Vanfleteren L.E., Franssen F.M. Personalised pulmonary rehabilitation in COPD. Eur. Respir. Rev. 2018;27:170125. doi: 10.1183/16000617.0125-2017.
    1. Agusti A., Bel E., Thomas M., Vogelmeier C., Brusselle G., Holgate S., Humbert M., Jones P., Gibson P.G., Vestbo J., et al. Treatable traits: Toward precision medicine of chronic airway diseases. Eur. Respir. J. 2016;47:410–419. doi: 10.1183/13993003.01359-2015.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit